Cellectis reveals POC for smart T-cells that recognize tumors
Category: #health  By Mateen Dalal  Date: 2019-11-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cellectis reveals POC for smart T-cells that recognize tumors

Cellectis, a French biopharmaceutical company that aims to innovate immunotherapies based on gene-edited allogeneic CAR T-cells, recently revealed a report issued in Nature Communications that explains a proof-of-concept (POC) for cell pathway’s rewiring to produce extremely intelligent T-cells which could identify cancerous tumors and create a micro secretion of therapeutic proteins.

This advancement could eventually enhance the capability of T-cells to fight cancer and redesign the tumor microenvironment. Moreover, by using gene editing procedures to rewire the CD25, PD1 and TCRα genes, the study allowed CAR T-cells to micro secrete the IL-12, pro-inflammatory cytokine, in a tumor.

Reportedly, this procedure was done in a time-dependent manner which would further lay the foundation for the next generation of highly active, potentially safer and tightly controlled CAR T-cell therapies.

Speaking on the move, Dr. Philippe Duchateau, Ph.D., Chief Scientific Officer, Cellectis, said that the conversation near the tumor microenvironment has become a trending issue in the CAR T-cell space, and with the current developments in gene-editing technologies, particularly TALEN®, has opened the possibility to manipulate T-cell’s way to regulate itself to adjust with its environment.

Duchateau added that, with successively rewiring their natural regulatory activities and seamless modification of various genes, this method would trigger T-cells to produce therapeutic proteins of interest in a strongly localized and controlled manner. 

Additionally, the company has changed the current T-cells into powerful and precise micro-robots which could spray IL-12 precisely onto cancer cells. This would prevent the potential toxicity of IL-12’s systemic injection while improving CAR-T activity.

Earlier this year, Cellectis had made headlines when it revealed that it has signed a manufacturing service agreement that covers clinical manufacturing of the company’s allogeneic UCART drug candidates pursuing hematological malignancies. 

Reportedly, the manufacturing is expected to be conducted at Lonza's GMP facility which is located in Geleen, Netherlands.

Source Credit: https://www.cellectis.com/en/press/cellectis-publishes-creation-of-smart-car-t-cells-for-potentially-safer-more-effective-treatments-for-cancer-in-nature-communications/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Merck & Co. to acquire ArQule to advance leadership in oncology
Merck & Co. to acquire ArQule to advance leadership in oncology
By Mateen Dalal

Merck, a renowned American pharmaceutical company also known as MSD outside Canada and the United States, reportedly announced the acquisition of ArQule, a US-based biopharmaceutical firm focused on finding novel therapies for cancer treatment. The c...

IMV announces updated data for Phase 2 DPX-Survivac trial in r/r DLBCL
IMV announces updated data for Phase 2 DPX-Survivac trial in r/r DLBCL
By Mateen Dalal

The updated results were presented in poster session at the ASH annual meeting   The study shows strong data for DPX-Survivac in combination with pembrolizumab IMV Inc., a clinical-stage biopharmaceutical firm focusing on immunotherapy in ...

Kura Oncology announces regulatory & clinical updates for Tipifarnib
Kura Oncology announces regulatory & clinical updates for Tipifarnib
By Mateen Dalal

Kura Oncology, Inc., a biopharmaceutical firm based in the U.S., has recently revealed regulatory and clinical updates of its foremost drug candidate, Tipifarnib, designed to target AITL (angioimmunoblastic T-cell lymphoma). The update included previ...